ArticleInternational journal of molecular sciences2023
Clinical Phenotypes of Progressive Supranuclear Palsy-The Differences in Interleukin Patterns.
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Peripheral immune profile and neutrophil-to-lymphocyte ratio in progressive supranuclear palsy: Case-control study and meta-analysis.European journal of neurology · 2024Pooled it
- Blood-Derived Inflammatory Indices Across Essential Tremor, Parkinson's Disease, and Progressive Supranuclear Palsy: An Exploratory Retrospective Analysis.Diseases (Basel, Switzerland) · 2026Article
- Distinct plasma inflammatory signatures reflect disease severity and progression in progressive supranuclear palsy: a prospective cohort study.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Review
- Assessment of Mitochondrial DNA Copy Number in Progressive Supranuclear Palsy Patients: Evidence From a Pilot Study.European journal of neurology · 2026Article
- From clinical phenotypes to molecular stratification: early differential diagnosis of four-repeat tauopathies.Frontiers in aging neuroscience · 2026Review
- Peripheral and central inflammation in progressive supranuclear palsy syndrome: an immunological and imaging neuroinflammation study.Frontiers in immunology · 2026Article
- The neutrophil-to-lymphocyte ratio in Parkinson's disease: a systematic review and meta-analysis of its association with differential diagnosis, severity, and prognosis.Clinical parkinsonism & related disorders · 2026Review
- Inflammatory and Neurotrophic Factors and Their Connection to Quality of Life in Progressive Supranuclear Palsy-Single-Center Study.International journal of molecular sciences · 2025Article
- Potential Role of Transferrin and Vascular Cell Adhesion Molecule 1 in Differential Diagnosis Among Patients with Tauopathic Atypical Parkinsonian Syndromes.Diagnostics (Basel, Switzerland) · 2025Article
- Elevated Mean Corpuscular Hemoglobin Concentration as a Potential Peripheral Biomarker of Parkinson's Disease: A Pilot Case-Control Study in a Mexican Population.Brain sciences · 2025Article
- Role of the Intestinal Microbiota in the Molecular Pathogenesis of Atypical Parkinsonian Syndromes.International journal of molecular sciences · 2025Review
- The Genetic Background of the Immunological and Inflammatory Aspects of Progressive Supranuclear Palsy.International journal of molecular sciences · 2025Review
- Possible Significance of Neutrophil-Hemoglobin Ratio in Differentiating Progressive Supranuclear Palsy from Depression: A Pilot Study.Diseases (Basel, Switzerland) · 2025Article
- Magnetic Resonance Imaging in the Neuroimaging of Progressive Supranuclear Palsy-Parkinsonism Predominant: Limitations and Strengths in Clinical Evaluation.Diagnostics (Basel, Switzerland) · 2025Article
- The Significance of High-Density Lipoprotein-Derived Inflammatory Parameters in Atypical Parkinsonisms-Pilot Study.Journal of clinical medicine · 2025Article
- α-Synuclein Degradation in Brain Pericytes Is Mediated via Akt, ERK, and p38 MAPK Signaling Pathways.International journal of molecular sciences · 2025Article
- Association Between Levodopa with Inotrope Prescription and Mechanical Ventilation Dependence in People with Parkinson's Disease upon Septic Shock.Journal of clinical medicine · 2025Article
- Associations of eosinophil-to-monocyte ratio and C-reactive protein-to-high-density lipoprotein cholesterol ratio with early neurological deterioration after thrombolysis in acute ischemic stroke.Frontiers in neurology · 2025Article
- Increased tau-induced inflammatory responses are associated with a greater degree of atherosclerosis in progressive supranuclear palsy.Frontiers in aging neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Progressive supranuclear palsy (PSP) is an atypical parkinsonian syndrome based on tau pathology; its clinical phenotype differs, but PSP with Richardson's syndrome (PSP-RS) and the PSP parkinsonism predominant (PSP-P) variant remain the two most common manifestations. Neuroinflammation is involved in the course of the disease and may cause neurodegeneration. However, an up-to-date cytokine profile has not been assessed in different PSP phenotypes. This study aimed to evaluate possible differences in neuroinflammatory patterns between the two most common PSP phenotypes. Serum and cerebrospinal fluid (CSF) concentrations of interleukin-1 beta (IL-1β) and IL-6 were analyzed using enzyme-linked immunosorbent assay (ELISA) kits in 36 study participants-12 healthy controls and 24 patients with a clinical diagnosis of PSP-12 PSP-RS and 12 PSP-P. Disease duration among PSP patients ranged from three to six years. All participants underwent basic biochemical testing, and neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) values were calculated. Due to a lack of neuropathological examinations, as all patients remain alive, total tau levels were assessed in the CSF. Tau levels were significantly higher in the PSP-P and PSP-RS groups compared to the healthy controls. The lowest concentrations of serum and CSF interleukins were observed in PSP-RS patients, whereas PSP-P patients and healthy controls had significantly higher interleukin concentrations. Furthermore, there was a significant correlation between serum IL-6 levels and PLR in PSP-RS patients. The results indicate the existence of distinct neuroinflammatory patterns or a neuroprotective role of increased inflammatory activity, which could cause the differences between PSPS phenotypes and clinical course. The causality of the correlations described requires further studies to be confirmed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.